Nobuhiro Asai, Yoshihiro Ohkuni and Norihiro Kaneko
A-60 years old woman has been observed in our outpatient clinic for several years. She has been uncontrolled for her asthma despite multi-drug therapy; [Fluticazone (FP) 800 μg/day+Salmeterol(SM l00 μg+Montelukast 10 mg+Theophilline 200 mg/day], presenting asthma control test (ACT) score as 13. We added Ciclesonide (CIC) to her therapy and replaced FP and SM with BFC. As a result, her pulmonary function and ACT score improved. The counts of eosinophils in induced sputum decreased significantly. Furthermore, during an observation period of 9 months, she had neither had an emergency visit nor an asthma exacerbation. While some physicians previously reported efficacy of Inhaled corticosteroids (ICS) combination therapy of FP and Beclomethasone (BDP), there are no reports concerning the efficacy and tolerability of ICS combination therapy of Budesonide/Folmoterol combination (BFC) and Ciclesonide-hydrofluoroalkane (CIC-HFA). This is the first case report of a persistent asthma patient succesfully treated by the ICS combination therapy of BFC and CIC-HFA.
इस लेख का हिस्सा
English 
Spanish 
Chinese 
Russian 
German 
French 
Japanese 
Portuguese 
Telugu 